Thyrotoxic atrial fibrillation.
Atrial fibrillation is the most common cardiac complication of hyperthyroidism and occurs in 15% of patients with hyperthyroidism. It is associated with a higher risk of thromboembolism that often involves the central nervous system. Oral anticoagulation is important in the majority of these patients to prevent thromboembolic complications. These patients require adjustment in the dose of various rate-controlling agents because of increased clearance associated with hyperthyroidism and a decrease in warfarin dosage because of increased clearance of vitamin K-dependent clotting factors. The management of thyrotoxic atrial fibrillation is summarized in this clinical review.
Parmar
Malvinder S
MS
Northern Ontario School of Medicine, Laurentian University, Sudbury, Canada.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D013956:Antithyroid Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D013971:Thyrotoxicosis / Q000150:complications* / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D013956:Antithyroid Agents